GEMP Gemphire Therapeutics Inc

Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that management will be making presentations at the 30th Annual ROTH Conference and the H.C. Wainwright 2nd Annual NASH Investor Conference.

Presentation Details30th Annual ROTH Conference
Date:Time:Panel:Panelist:Location:		Tuesday, March 137am Pacific Time/10am Eastern TimeIt Is Not a Myth, It Is Real:  Pediatric NASHSeth Reno, Chief Commercial OfficerRitz Carlton, Laguna Niguel, California
Date:Time:Panel:Panelist:Location:		Tuesday, March 138am Pacific Time/11am Eastern TimeLove Your Liver, Love Your Heart:  Cardio-Metabolic MoleculesSteve Gullans, Ph.D., Interim Chief Executive OfficerRitz Carlton, Laguna Niguel, California
H.C. Wainwright 2nd Annual NASH Investor Conference
Date:Time:Presenter:Location:Webcast:		Monday, March 198:40am Eastern TimeSteve Gullans, Ph.D., Interim Chief Executive OfficerSt. Regis Hotel, New York Cityhttp://wsw.com/webcast/hcw3/gemp/

About GemphireGemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.  The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors.  Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD.  Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151.  Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.

Contact:Andrew McDonald, Ph.D.LifeSci Advisors, LLC(646) 597-6987

Jeff Mathiesen, CFOGemphire Therapeutics Inc.(734)-245-1700